Tharim­mune's pub­lic of­fer­ing; Cul­mi­na­tion Bio rais­es $10M; Pep­per Bio's seed round led by NFX

Tharim­mune clos­es $11M in pub­lic of­fer­ing: The com­pa­ny, which is de­vel­op­ing ther­a­pies that aim to treat rare, in­flam­ma­to­ry, and on­co­log­ic con­di­tions, an­nounced Thurs­day that it sold 11 mil­lion shares of com­mon stock for $1 per share. Tharim­mune’s stock $THAR was down about 6% in trad­ing on Fri­day morn­ing.

Da­ta start­up rais­es $10M from Am­gen and Mer­ck funds: Cul­mi­na­tion Bio re­ceived $10 mil­lion from Am­gen Ven­tures and the Mer­ck Glob­al Health In­no­va­tion Fund, it said Thurs­day. The com­pa­ny is build­ing a data­base of de-iden­ti­fied pa­tient da­ta sourced from elec­tron­ic health records and biospec­i­mens that it says can help bio­phar­mas more quick­ly iden­ti­fy po­ten­tial pa­tients for clin­i­cal re­search.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER